CITIUS ONCOLOGY, INC.
No enriched coverage for $CTOR in the last 7 days.
No SEC Form 4 filings for $CTOR in the last 30 days.
See all $CTOR insider activity →CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 29, 2026, Citius Oncology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders elected the following Class II directors for a
Citius Oncology (NASDAQ:CTOR) shares fell about 10% premarket after fiscal Q3 revenue missed forecasts. Revenue was $1.5M versus $12.52M consensus, with a loss of $0.34/share versus an expected $0.03/share. LYMPHIR institutional vial orders rose 31% sequentially to 926, and 44 institutions have prescribed. Cash was $16.6M at June 30, 2026.
Citius Oncology (Nasdaq: CTOR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026 and updated on LYMPHIR launch. Revenues were $1.5M for the quarter and $7.1M for nine months. Cash was $16.6M. LYMPHIR orders rose, with 44 institutions ordering since launch and institutional vials up 31% sequentially to 926 in Q3.
Recent CTOR coverage spans financial news, earnings and corporate actions.
Routine governance filing with no material operational change.
The earnings miss is the dominant near-term driver, while LYMPHIR institutional vial orders and payer coverage are offsetting positives that may limit downside.
The update provides fresh demand and revenue-recognition context for LYMPHIR, plus new commercial expansion and early combination-study response signals.
The filing provides fresh, decision-relevant operating metrics for LYMPHIR launch momentum plus updated cash and expense trajectory.
Board expansion and an independent director appointment are typically low-impact for near-term fundamentals, but can signal governance refresh.
AlphAI scores every news story that mentions CTOR with an AI model for sentiment and relevance, and aggregates insider trades from CITIUS ONCOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 29, 2026, Citius Oncology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders elected the following Class II directors for a
1 min readCitius Oncology (NASDAQ:CTOR) shares fell about 10% premarket after fiscal Q3 revenue missed forecasts. Revenue was $1.5M versus $12.52M consensus, with a loss of $0.34/share versus an expected $0.03/share. LYMPHIR institutional vial orders rose 31% sequentially to 926, and 44 institutions have prescribed. Cash was $16.6M at June 30, 2026.
4 min readCitius Oncology (Nasdaq: CTOR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026 and updated on LYMPHIR launch. Revenues were $1.5M for the quarter and $7.1M for nine months. Cash was $16.6M. LYMPHIR orders rose, with 44 institutions ordering since launch and institutional vials up 31% sequentially to 926 in Q3.
6 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered
6 min readCITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., August 12, 2026 — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Phar
2 min readCitius Oncology (Nasdaq: CTOR) reported commercial progress for LYMPHIR (denileukin diftitox-cxdl). It said new institutional accounts ordering LYMPHIR rose 78% quarter over quarter to 42 institutions, and wholesaler vial orders increased 31% in Q2 2026. Company estimates the initial CTCL market exceeds $400 million.
4 min readCitius Oncology (Nasdaq: CTOR) said it is expanding its LYMPHIR launch team, adding 21 field commercial professionals and eight medical science liaisons, with nationwide onboarding expected by August 2026. The buildout was facilitated by May 2026 financing and executed by EVERSANA. The company cites near 100% payer coverage and expects continued order and patient adoption growth in 2H 2026.
4 min readCitius Pharmaceuticals (Nasdaq: CTXR) secured $3.8 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program. This funding, obtained on February 24, 2026, strengthens the company's financial flexibility. The capital is designated to support the commercial launch of LYMPHIR and advance its late-stage pipeline programs.
2 min readCitius Oncology, a subsidiary of Citius Pharmaceuticals, has signed an exclusive distribution agreement with Unipha to make Lymphir (denileukin diftitox-cxdl) available outside the USA. This marks Citius Oncology's third international distribution partnership, expanding global access for their targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Lymphir is intended for Stage I-III CTCL cases after at least one prior systemic therapy.
4 min readCitius Pharmaceuticals ( NASDAQ:CTXR ) , a late-stage biopharmaceutical company focused on developing and commercializing critical care therapies, reported its earnings for the fiscal third quarter of 2025 on August 12, 2025.
3 min read
